Local-regional recurrence following neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–positive clinical stage 2 to 3 breast cancer
- Citation:
- Ann Surg Oncol vol 30 (4) 2111-8
- Year:
- 2023
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 12
- Parents:
- 3171
- Children:
- None
- Pharmas:
- CTI BioPharma Corp, Pfizer, Novartis
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233253, UG1CA233329, UG1CA233302, UG1CA232760; R01-CA095614, U01-CA114722
- Corr. Author:
- Authors:
- Kelly K. Hunt Vera J. Suman Hannah F. Wingate A. Marilyn Leitch Gary Unzeitig Judy C. Boughey Funda Meric-Bernstam Matthew J. Ellis John Olson
- Networks:
- GA005, LAPS-MN026, LAPS-TX011, LAPS-TX035, TX041, TX190
- Study
- ACOSOG-Z1031
- Multiple Studies, or Legacy Studies in Alliance Study:
- Alliance-A011106
- Phases:
- 3, 3
- Keywords: